Otaegi-Ugartemendia Maddalen, Matheu Ander, Carrasco-Garcia Estefania
Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain.
CIBER de Fragilidad y Envejecimiento Saludable (CIBERfes), 28029 Madrid, Spain.
Cancers (Basel). 2022 Mar 11;14(6):1457. doi: 10.3390/cancers14061457.
Gastric cancer (GC) is the fourth leading cause of cancer death worldwide, with an average 5-year survival rate of 32%, being of 6% for patients presenting distant metastasis. Despite the advances made in the treatment of GC, chemoresistance phenomena arise and promote recurrence, dissemination and dismal prognosis. In this context, gastric cancer stem cells (gCSCs), a small subset of cancer cells that exhibit unique characteristics, are decisive in therapy failure. gCSCs develop different protective mechanisms, such as the maintenance in a quiescent state as well as enhanced detoxification procedures and drug efflux activity, that make them insusceptible to current treatments. This, together with their self-renewal capacity and differentiation ability, represents major obstacles for the eradication of this disease. Different gCSC regulators have been described and used to isolate and characterize these cell populations. However, at the moment, no therapeutic strategy has achieved the effective targeting of gCSCs. This review will focus on the properties of cancer stem cells in the context of therapy resistance and will summarize current knowledge regarding the impact of the gCSC regulators that have been associated with GC chemoradioresistance.
胃癌(GC)是全球癌症死亡的第四大主要原因,平均5年生存率为32%,出现远处转移的患者5年生存率为6%。尽管胃癌治疗取得了进展,但仍会出现化疗耐药现象,促进复发、扩散并导致预后不良。在此背景下,胃癌干细胞(gCSCs)作为一小部分具有独特特征的癌细胞,在治疗失败中起决定性作用。gCSCs形成了不同的保护机制,如维持静止状态以及增强解毒程序和药物外排活性,这使得它们对当前治疗不敏感。这连同它们的自我更新能力和分化能力,成为根除这种疾病的主要障碍。已经描述了不同的gCSC调节因子,并用于分离和表征这些细胞群体。然而,目前尚无治疗策略能够有效靶向gCSCs。本综述将聚焦于治疗耐药背景下癌症干细胞的特性,并总结关于与胃癌放化疗耐药相关的gCSC调节因子影响的当前知识。